Clinical Policy: Efinaconazole (Jublia)
Reference Number: HIM.PA.25
Effective Date: 02.01.17
Last Review Date: 02.19
Line of Business: HIM

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Efinaconazole (Jublia<sup>®</sup>) is an azole antifungal.

FDA Approved Indication(s)
Jublia is indicated for the topical treatment of onychomycosis of the toenails due to <i>Trichophyton rubrum</i> and <i>Trichophyton mentagrophytes</i>.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

I. Initial Approval Criteria
A. Onychomycosis (must meet all):
   1. Diagnosis of onychomycosis of the toenails;
   2. Age ≥ 18 years;
   3. Failure of a 12-week trial of oral terbinafine at up to maximally indicated doses within the past 12 months, unless contraindicated or clinically significant adverse effects are experienced;
   4. Failure of ciclopirox 8% topical solution, unless contraindicated or clinically significant adverse effects are experienced;
   5. Request does not exceed 8 mL per 30 days.

   Approval duration: 48 weeks

B. Other diagnoses/indications
   1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace.

II. Continued Therapy
A. Onychomycosis (must meet all):
   1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
   2. Member is responding positively to therapy;
   3. If request is for a dose increase, new dose does not exceed 8 mL per 30 days.

   Approval duration: 48 weeks
B. Other diagnoses/indications (must meet 1 or 2):
   1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
   Approval duration: Duration of request or 48 weeks (whichever is less); or
   2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace.

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – HIM.PHAR.21 for health insurance marketplace or evidence of coverage documents.

IV. Appendices/General Information
   Appendix A: Abbreviation/Acronym Key
   FDA: Food and Drug Administration

   Appendix B: Therapeutic Alternatives
   This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>terbinafine (Lamisil®)</td>
<td>Toenail onychomycosis: 250 mg PO once daily for 12 weeks</td>
<td>250 mg/day</td>
</tr>
<tr>
<td>ciclopirox 8% topical solution (Penlac®)</td>
<td>Apply once daily (preferably at bedtime or eight hours before washing) to all affected nails with the applicator brush provided. Daily applications should be made over the previous coat and removed with alcohol every seven days. This cycle should be repeated throughout the duration of therapy. The safety and efficacy of using ciclopirox daily for &gt; 48 weeks have not been established.</td>
<td>See dosing regimen</td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings
None reported

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onychomycosis</td>
<td>Apply to affected toenails once daily for 48 weeks</td>
<td>Once daily</td>
</tr>
</tbody>
</table>
VI. Product Availability
Solution: 10%

VII. References

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy created.</td>
<td>12.16</td>
<td>02.17</td>
</tr>
<tr>
<td>1Q18 annual review</td>
<td>11.02.17</td>
<td>02.18</td>
</tr>
<tr>
<td>- Removed laboratory testing related to confirmation of fungal infection; added age restriction as safety and effectiveness in pediatrics have not been established - ---- Modified duration of trial of terbinafine from 3 months to 12-weeks per Lamisil PI and American Family Physician; specified a timeframe of within the past 12 months for oral terbinafine trial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Re-auth: removed requirement that member has not used Jublia daily ≥48 weeks as this would be difficult to verify objectively; modified approval duration from “up to 48 weeks of treatment (total)” to 48 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- References reviewed and updated.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1Q 2019 annual review: no significant change from previously approved policy; references reviewed and updated.</td>
<td>09.27.18</td>
<td>02.19</td>
</tr>
</tbody>
</table>

Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering
CLINICAL POLICY
Efinaconazole

benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage
decisions and the administration of benefits are subject to all terms, conditions, exclusions and
limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy,
contract of insurance, etc.), as well as to state and federal requirements and applicable Health
Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting
may not be the effective date of this clinical policy. This clinical policy may be subject to
applicable legal and regulatory requirements relating to provider notification. If there is a
discrepancy between the effective date of this clinical policy and any applicable legal or
regulatory requirement, the requirements of law and regulation shall govern. The Health Plan
retains the right to change, amend or withdraw this clinical policy, and additional clinical
policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is
not intended to dictate to providers how to practice medicine. Providers are expected to exercise
professional medical judgment in providing the most appropriate care, and are solely responsible
for the medical advice and treatment of members. This clinical policy is not intended to
recommend treatment for members. Members should consult with their treating physician in
connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent
judgment and over whom the Health Plan has no control or right of control. Providers are not
agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and
distribution of this clinical policy or any information contained herein are strictly
prohibited. Providers, members and their representatives are bound to the terms and conditions
expressed herein through the terms of their contracts. Where no such contract exists, providers,
members and their representatives agree to be bound by such terms and conditions by providing
services to members and/or submitting claims for payment for such services.

Note:
For Health Insurance Marketplace members, when applicable, this policy applies only when
the prescribed agent is on your health plan approved formulary. Request for non-formulary drugs
must be reviewed using the non-formulary policy; HIM.PA.103.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by
Centene Corporation and are protected by United States copyright law and international
copyright law. No part of this publication may be reproduced, copied, modified, distributed,
displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise
published without the prior written permission of Centene Corporation. You may not alter or
remove any trademark, copyright or other notice contained herein. Centene® and Centene
Corporation® are registered trademarks exclusively owned by Centene Corporation.